Tanja Rixecker

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen et al. · Blood · 2012 · 237 citations · Full text

Pharmacy, Hematology, Pharmacokinetics +16

Suboptimal dosing of rituximab in male and female patients with DLBCL

Michael Pfreundschuh, Carsten Müller, Samira Zeynalova et al. · Blood · 2013 · 141 citations

Pharmacy, Oncology, Pharmacotherapy +10

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova et al. · Journal of Clinical Oncology · 2014 · 86 citations

Pharmacy, Oncology, Pharmacokinetics +17

Optimization of rituximab for the treatment of <scp>DLBCL</scp>: increasing the dose for elderly male patients

Michael Pfreundschuh, Niels Murawski, Samira Zeynalova et al. · British Journal of Haematology · 2017 · 55 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +17

Association of NADPH Oxidase Polymorphisms with Anthracycline-Induced Cardiotoxicity in the RICOVER-60 Trial of Patients with Aggressive CD20 ⁺ B-Cell Lymphoma

Annegret Reichwagen, Marita Ziepert, Markus Kreuz et al. · Pharmacogenomics · 2015 · 51 citations

Medicine, Immunology, Oncology +17